We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000623
First Posted: October 28, 1999
Last Update Posted: March 4, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Information provided by:
New England Research Institutes
  Purpose
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Condition Intervention
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Thalassemia Clinical Research Network (TCRN)

Resource links provided by NLM:


Further study details as provided by New England Research Institutes:

Primary Outcome Measures:
  • Vary by protocol

Estimated Enrollment: 1000
Study Start Date: July 2000
Study Completion Date: July 2006
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please refer to specific studies for eligibility criteria.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000623


Locations
United States, California
Children's Hospital Oakland
Oakland, California, United States, 94609
United States, Massachusetts
Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
Weill Medical College of Cornell University
New York, New York, United States, 10021
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
New England Research Institutes
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Investigators
Principal Investigator: Alan R. Cohen, MD Children's Hospital of Philadelphia
Principal Investigator: Patricia J. Giardina, MD Weill Medical College of Cornell University
Principal Investigator: Ellis J. Neufeld, MD, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Nancy F. Olivieri, MD Toronto General Hospital
Principal Investigator: Elliott P. Vichinsky, MD Children's Hospital & Research Center Oakland
Principal Investigator: Sonja McKinlay, PhD New England Research Institutes, Inc.
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000623     History of Changes
Other Study ID Numbers: 317
U01HL065232 ( U.S. NIH Grant/Contract )
U01HL065233 ( U.S. NIH Grant/Contract )
U01HL065238 ( U.S. NIH Grant/Contract )
U01HL065239 ( U.S. NIH Grant/Contract )
U01HL065244 ( U.S. NIH Grant/Contract )
U01HL065260 ( U.S. NIH Grant/Contract )
First Submitted: October 27, 1999
First Posted: October 28, 1999
Last Update Posted: March 4, 2014
Last Verified: July 2006

Keywords provided by New England Research Institutes:
chelator
iron
transfusion
anemia
thalassemia

Additional relevant MeSH terms:
Anemia
Osteoporosis
Thalassemia
Iron Overload
Hematologic Diseases
beta-Thalassemia
Hypertension, Pulmonary
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
Iron Metabolism Disorders
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Decitabine
Deferiprone
Deferoxamine
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents
Antimetabolites, Antineoplastic
Antimetabolites